Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

被引：0
|
作者：
Fuchs, Charles S.
Denker, Andrew E.
Tabernero, Josep
Van Cutsem, Eric
Ohtsu, Atsushi
Lam, Baohoang
Koshiji, Minori
Bang, Yung-Jue
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Merck & Co Inc, Kenilworth, NJ USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium
[5] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan
[6] Seoul Natl Univ, Coll Med, Seoul, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
10.1200/jco.2015.33.15_suppl.tps4135
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4135
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Pembrolizumab versus paclitaxel as second-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Phase 3 KEYNOTE-061 study.
    Ohtsu, Atsushi
    Tabernero, Josep
    Bang, Yung-Jue
    Fuchs, Charles S.
    Sun, Linda
    Wang, Zhen
    Csiki, Ildiko
    Koshiji, Minori
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [32] Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary.
    Varadhachary, Gauri R.
    Raghav, Kanwal Pratap Singh
    Pant, Shubham
    Janku, Filip
    Fu, Siqing
    Hong, David S.
    Piha-Paul, Sarina Anne
    Colen, Rivka R.
    Subbiah, Vivek
    Painter, Jeane
    Tsimberidou, Apostolia Maria
    Stephen, Bettzy
    Karp, Daniel D.
    McQuinn, Lacey
    Mendoza, Tito R.
    Hess, Kenneth R.
    Meric-Bernstam, Funda
    Naing, Aung
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [33] Phase II study of epacadostat with pembrolizumab in metastatic or unresectable gastroesophageal junction and gastric adenocarcinoma requiring paired biopsies.
    Kardosh, Adel
    Tseng, Diane
    Sahaf, Bita
    Zomet, Ativ
    Krupa, Julia
    Fisher, George A.
    Wang, David S.
    Mackall, Crystal
    Kunz, Pamela L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [34] Phase II trial of sorafenib in esophageal (E) and gastroesophageal junction (GEJ) cancer: Response observed in adenocarcinoma.
    Ilson, D.
    Shah, M. A.
    Kelsen, D. P.
    Janjigian, Y. Y.
    Tang, L. H.
    Campbell, J.
    Fuqua, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [35] Assessment of Pembrolizumab Therapy for the Treatment of Microsatellite Instability-High Gastric or Gastroesophageal Junction Cancer Among Patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 Clinical Trials
    Chao, Joseph
    Fuchs, Charles S.
    Shitara, Kohei
    Tabernero, Josep
    Muro, Kei
    Van Cutsem, Eric
    Bang, Yung-Jue
    De Vita, Ferdinando
    Landers, Gregory
    Yen, Chia-Jui
    Chau, Ian
    Elme, Anneli
    Lee, Jeeyun
    Ozguroglu, Mustafa
    Catenacci, Daniel
    Yoon, Harry H.
    Chen, Erluo
    Adelberg, David
    Shih, Chie-Schin
    Shah, Sukrut
    Bhagia, Pooja
    Wainberg, Zev A.
    JAMA ONCOLOGY, 2021, 7 (06) : 895 - 902
  • [36] An open single-arm phase II monotherapy study of pembrolizumab (MK-3475) in locally advanced/metastatic renal cell carcinoma (mRCC) (Keynote 427) - AN 40/16 of the AUO
    Rexer, H.
    Doehn, C.
    Bedke, J.
    UROLOGE, 2017, 56 (07): : 928 - 929
  • [37] Phase II study of zolbetuximab plus pembrolizumab in claudin 18.2: Positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ)-ILUSTRO Cohort 3.
    Klempner, Samuel J.
    Ajani, Jaffer A.
    Al-Batran, Salah-Eddin
    Bang, Yung-Jue
    Catenacci, Daniel V. T.
    Enzinger, Peter C.
    Ilson, David H.
    Kim, Sunnie
    Lordick, Florian
    Shah, Manish A.
    Shitara, Kohei
    Arozullah, Ahsan
    Park, Jung Wook
    Raizer, Jeffrey J.
    Van Cutsem, Eric
    Xu Rui-Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [38] Phase II trial of gefitinib for recurrent or metastatic esophageal or gastroesophageal junction (GEJ) cancer.
    Adelstein, DJ
    Rybicki, LA
    Carroll, MA
    Rice, TW
    Mekhail, T
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 321S - 321S
  • [39] Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: methodology of phase 3 randomized trial
    Harrington, K.
    Machiels, J. -P.
    Shin, S. W.
    Cohen, E.
    Burtness, B.
    Gause, C.
    Swift, A.
    Swaby, R.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2015, 26 : 5 - 6
  • [40] Pembrolizumab (MK-3475) versus standard treatment in patients with recurrent or metastatic head and neck cancer: Methodology of phase 3 randomized trial
    Machiels, J. -P.
    Shin, S. W.
    Cohen, E.
    Harrington, K.
    Burtness, B.
    Gause, C.
    Swift, A.
    Swaby, R.
    Le Tourneau, C.
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
12345